Hyperbranched dendritic nano-carriers for topical delivery of dithranol

Journal of Drug Targeting

Volumn 21, Issue 5, 2013, Pages 497-506

  Agrawal, Udita ^a   Mehra, Neelesh Kumar ^a   Gupta, Umesh ^a   Jain, N K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Dendrimers; Dithranol; Psoriasis; Topical drug delivery

Indexed keywords

DENDRIMER; DITHRANOL; POLYPROPYLENE; POLYPROPYLENE IMINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG PENETRATION; ENCAPSULATION; IN VITRO STUDY; NONHUMAN; PH; PRIORITY JOURNAL; PSORIASIS; RAT; SKIN IRRITATION; SPECTROSCOPY; TOPICAL DRUG ADMINISTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTHRALIN; BIOLOGICAL AVAILABILITY; DENDRIMERS; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; NANOPARTICLES; POLYPROPYLENES; PSORIASIS; RATS; SKIN; SKIN ABSORPTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878580596     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.771778     Document Type: Article

References (44)

1. Korotkii NG, Peslyak MY. Psoriasis as a result of b-streptococci inclusion into intestine microbiocenosis with increased permeability (concept of pathogenesis). Vestn Dermatol Venerol 2005; 1:9-18.
2. Dubey V, Mishra D, Dutta T, et al. Dermal and topical delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Rel 2007;123:148-254.
3. Nestle FO, Conrad C. Mechanisms of psoriasis. Drug Discov Today 2005;1:315-19.
4. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001;228:43-52.
5. Campalani E, Barker J. The clinical genetics of psoriasis. Curr Genomics 2005;6:51-60.
6. Gudjonsson JE, Johnston A, Sigmundottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:1-8.
7. Raza K, Katare OP, Setia A, et al. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul 2012. [Epub ahead of print]. doi:10.3109/02652048.2012.717115.
8. Reichert U, Jacques Y, Grangeret M, Schmidt R. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J Invest Dermatol 1985;84:130-4.
9. Suja EG, Rosaleen JA, Paul H, Paul GW. A simple RP-HPLC methods for the determination of the anti-psoriatic drug dithranol and its application in an in vitro cell uptake study. Curr Pharm Anal 2012;8:75-82.
10. Schroder JM. Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene production and LTB4-omega oxidation by human neutrophils. J Invest Dermatol 1986;87:624-49.
11. Schroder JM, Kosfeld U, Christophers E. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J Invest Dermatol 1985;85:30-4.
12. Kemeny L, Gross E, Arenberger P, Ruzicka T. Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)- HETE] receptors in a human epidermal cell line. Arch Dermatol Res 1991;283:333-6.
13. Lebwohl M, Ali S. Treatment of psoriasis. Part Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.
14. Thune P, Brolund L. Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol (Stockh) 1992;172:28-9.
15. Neubert R, Wohlrab W, Bendas C. Modelling drug penetration into human skin using a multilayer membranes system. Skin Pharmacol 1995;8:119-29.
16. Raza M, Negi P, Takyar S, et al. Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. J Microencapsul 2011;28:190-9.
17. Jain K, Kesharwani P, Gupta U, Jain NK. A review of glycosylated carriers for drug delivery. Biomaterials 2012;33:4166-86.
18. Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Exp Opin Drug Deliv 2013. [Epub ahead of print]. doi: 10.1517/174 25247.2013.751370.
19. Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichim Acta 2004;37:39-57.
20. Gajbhiye V, Jain NK. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2012;32:6213-25.
21. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009;109:49-87.
22. Gupta U, Dwivedi SK, Bid HK, et al. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm 2010;393:185-96.
23. Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated topical delivery: enhanced bioavailability of indomethacin. J Control Rel 2003;90:335-43.
24. Yiyun C, Na M, Tongwen X, et al. Topical delivery of nonsteroidal anti-inflammatory drug mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 2007;9:6562-95.
25. Venuganti VV, Perumal OP. Poly(amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation, and concentration. J Pharm Sci 2009;98:2345-56.
26. Rupp R, Rosenthal SL, Stanberry LR. VivaGel- (SPL7013 Gel): a candidate dendrimers-microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2007;2:561-6.
27. De Brabander-van den Berg EMM, Meijer EW. Poly (propylene imine) dendrimers: large scale synthesis by heterogenously catalyzed hydrogenation. Angew Chem Int Ed Engl 1993; 32:1308-11.
28. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005;295:221-33.
29. Higuchi T, Connors KA. Phase-solubility techniques. In: Reilly CN, ed. Advances in analytical chemistry and instrumentation. New York: John Wiley; 1965:117-212.
30. Wang JCT, Patel BG, Ehman CW, Lowe N. The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin. J Am Acad Dermatol 1987;16:812-20.
31. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system. Pharm Res 2000; 17:991-8.
32. Dubey V, Mishra D, Asthana A, Jain NK. Topical delivery of a pineal hormone: melatonin via elastic liposomes. Biomaterials 2006;27:3491-6.
33. Lopes LB, Bantley MVLB. Cyclosporin A in skin of samples from in vitro penetration studies may be assayed by a simple HPLC method. Braz J Pharm Sci 2005;41:477-82.
34. Shah KA, Date AA, Joshi MD, Patravate VB. Solid lipid nanoparticles of tretinion. potential in topical delivery. Int J Pharm 2007;345:163-71.
35. Draize J, Woodard G, Calvery H. Methods for the study of irritation and toxicity of substances topically applied to skin and mucous membranes. J Pharmacol Exp Ther 1944;82:377-90.
36. Gupta U, Agashe HB, Jain NK. Poly (propylene imine) dendrimers mediated solubility enhancement, effect of pH and functional groups of hydrophobes. J Pharm Sci 2007;10:358-67.
37. Pedziwiatr-Werbicka E, Ferenc M, Zaborski M, et al. Characterization of complexes formed by polypropylene imine dendrimers and anti-HIV oligonucleotides. Colloids Surf B: Biointerfaces 2011;83:360-6.
38. Piemi MPY, Korner D, Benita S, Marty JP. Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drug. J Control Rel 1999; 58:177-87.
39. Boas U, Christensen JB, Heegaard PMH, eds. Dendrimers: design, synthesis and chemical properties. In: Dendrimers in medicine and biotechnology new molecular tools. 1st ed. UK: The Royal Society of Chemistry; 2006:1-27.
40. Hong S, Bielinska AU, Mecke A, et al. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjugate Chem 2004;15:774-82.
41. Shcharbin D, Drapeza A, Loban V, et al. The breakdown of bilayer lipid membranes by dendrimers. Cell Mol Biol Lett 2006;11:242-8.
42. Mecke A, Uppuluri S, Sassanella TM, et al. Direct observation of lipid bilayer disruption by poly(amidoamine) dendrimers. Chem Phys Lipids 2004;132:3-14.
43. Van den berg BAI, Vroom J, Gerritsen H, et al. Interactions of elastic and rigid vesicles with human skin in vitro: electron microscopy and two-photon excitation microscopy. Biochim Biophys Acta 1999;146:155-73.
44. Honeywell-Nguyen PI, DeGraff AM, Groenink HWW, Bowstra JA. The in-vivo and in-vitro interactions of elastic and rigid vesicles with human skin. Biochim Biophys Acta 2002;1573: 130-40.